Cipla Explained: The $1 Pill That Saved 20 Lakh Lives
Business

Cipla Explained: The $1 Pill That Saved 20 Lakh Lives

In 2001, the yearly cost for HIV treatment was $15,000 (around ₹7 lakh) per patient. South Africa alone reported over 70% of HIV cases where citizens’ average annual wage was around $3,536 (₹1.6 lakh). Affording treatment that’s over four times the annual minimum wage was impossible for developing countries.   Then, Cipla entered the frame and offered a 96% reduction for the annual treatment. It's per-patient cost? $350 (around ₹16,800). This reduction brought the per-dose price as low as just $1 (around ₹48).

Continue Reading about 9 months ago
Mankind Pharma Explained: Will it Rise with BSV?
Business

Mankind Pharma Explained: Will it Rise with BSV?

Have you heard of Mankind Pharma? At some point or another, almost everyone has used its products or seen its advertisements on TV.

Continue Reading about 10 months ago
Mankind Pharma IPO: Should you invest?
Big Shots

Mankind Pharma IPO: Should you invest?

Investors have greatly contributed to the success of Initial Public Offerings (IPO) in the country. IPOs have been a popular way for companies to raise capital and offer shares to the public.  I would say that investing in IPOs is like a game of treasure hunt, with investors searching for hidden gems among the sea of offerings. And we have yet another offering. 

Continue Reading about 2 years ago
Best Pharma Stocks in India
Invest

Best Pharma Stocks in India

Sectors, be it banking, auto, agriculture, airlines, defence, paints, steel, textile, the list goes on. Whatever the sector is it has separate importance in the economy. Moreover, each industry has an economy and workings of its own such as each sector has its own segments, each company in the sector has a different business model and whatnot. 

Continue Reading about 3 years ago
Ranbaxy : Family Feud, Scams and More
Business

Ranbaxy : Family Feud, Scams and More

Everyone has a role in their family, mine is Dawai ka Ramu Kaka(I am responsible for fetching medicines in my household, sometimes mine too).

Continue Reading about 3 years ago
Top 5 Pharma Stocks in India
Invest

Top 5 Pharma Stocks in India

“Ever since human species came into existence, wounds and diseases have been part and parcel of their life”.

Continue Reading about 3 years ago
E pharmacy: will it change the way we buy medicines?
Startups

E pharmacy: will it change the way we buy medicines?

With lives getting busier, health often takes a back seat! Medicines, for instance, are oft-overlooked. And if technology can heal this wound, what stops you, eh?

Continue Reading about 4 years ago
What went wrong with India’s Vaccination strategy?
Macro Moves

What went wrong with India’s Vaccination strategy?

What is believed to be the world’s largest vaccination drive isn’t all that rosy! Read this piece to make sense of how India messed up its covid vaccination strategy.

Continue Reading about 4 years ago
Why USFDA increases strict check on Indian Pharmaceutical Companies?
Macro Moves

Why USFDA increases strict check on Indian Pharmaceutical Companies?

USFDA Whip Continues on Indian Pharma. It’s raining warning letters and inspection reports on Indian pharmaceuticals. Why is this a matter of concern?

Continue Reading about 5 years ago
Cadila healthcare- Stock Analysis
Invest

Cadila healthcare- Stock Analysis

Cadila Healthcare is a 65-year-old pharmaceutical company with its presence in India, Europe, Africa, Middle East, Mexico, Brazil and most importantly, the USA. Headquartered in Ahmedabad, the company has over 35 manufacturing facilities and over 23500 employees. The company has its presence across the pharmaceutical value chain of research, development, manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (‘APIs’), animal healthcare products and consumer wellness products. The Company is also engaged in research and development activities focused across the value chain of API process development, generics development, biologics, vaccines, and New Chemical Entities (‘NCE’). What is Good?

Continue Reading about 6 years ago